Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine.

BioMarin Pharmaceutical

With six products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs. The company is also currently conducting a clinical trial of an AAV-based potential gene therapy for hemophilia A.

VIVET Therapeutics

Vivet Therapeutics is a clinical-stage biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.
Vivet’s lead program, VTX-801, is currently under clinical development for Wilson Disease (GATEWAY – Phase 1/2 Clinical Trial of VTX-801).
VTX-801 is a novel investigational gene therapy for Wilson Disease, which has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) and the European Commission (EC) and Fast Track designation by the FDA. Wilson Disease, a rare genetic disorder, is caused by mutations in the gene encoding the ATP7B protein, which reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurologic symptoms and potentially death.
Vivet is building a diversified gene therapy pipeline based on novel recombinant adeno-associated virus (rAAV) and is also working on technological platforms addressing key challenges of gene therapy, including sustained therapeutic gene expression in young patients, adults and immune responses towards the viral vector.

Gyros Protein Technologies

Gyros Protein Technologies provides enabling bioanalytical solutions helping scientists increase biomolecule performance and productivity in pre-clinical/clinical development, and bioprocess applications. For bioanalysis, the nanoliter-scale Gyrolab® immunoassay platforms (Gyrolab xPand, Gyrolab xPlore™) and Gyrolab immunoassay Kits (Gyrolab p24 Kit, Gyrolab AAV9 Titer Kit, Gyrolab AAVX Titer Kit [serotypes 1-8 and 10]), and Solutions for HEK 293 HCP and endonuclease impurities are used by scientists in leading pharmaceutical, biotech and CRO/CMO companies in the development and manufacturing of biotherapies including cell and gene therapies. Gyrolab immunoassays provide key workflow advantages of speed, automation, and low sample and reagent usage with a wide dynamic range in applications including PK/PD, immunogenicity, and analysis of bioprocess-related impurities. Gyros Protein Technologies is part of the Biopharmaceutical Division of Mesa Laboratories, Inc.

SwanBio Therapeutics

SwanBio Therapeutics aims to bring life-changing treatments to people with devastating, inherited neurological conditions. The company is advancing a pipeline of gene therapies designed to be delivered intrathecally to address targets within both the central and peripheral nervous systems. SwanBio’s lead program is the first clinical-stage AAV-based gene therapy for the treatment of adrenomyeloneuropathy (AMN).


Cergentis is a privately held genomics company and has developed and patented the Targeted Locus Amplification (TLA) technology. TLA is a widely published Next Generation Sequencing (NGS) technology that offers unique advantages in the implementation of advanced genetic engineering.
We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provides services for the support in R&D in these fields. Founded in 2012, Cergentis has established itself as a trusted partner and leader in robust and rapid genetic characterization of genetically engineered cell lines, cell and gene therapy products and transgenic (animal) models for the global biopharmaceutical industry as well as leading research institutes worldwide. It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.


SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are the leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.

SparingVision is backed by high-quality international investors including 4BIO Capital, AdBio Partners, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital, Ysios Capital.


Powering innovation on its journey from lab to life. 
ViroCell Biologics is a UK-based innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. 

Malvern Panalytical

Malvern Panalytical is a world leader in analytical characterization, creating expert solutions for the challenges associated with maximizing productivity, developing better quality products and getting them to market faster. We provide superior, customer-focused technologies, solutions and services which deliver tangible economic impact through chemical, biophysical and structural analysis. 

ClearPoint Neuro

ClearPoint Neuro partners with pharmaceutical and biologics companies through all stages of therapy development, leveraging our FDA-cleared and CE marked solutions for direct CNS infusions.*  ClearPoint offers services, devices, and software to enable MRI-guided intraparenchymal and CSF delivery of gene, cell, and other therapies.  Our team has the expertise to guide you from the benchtop, into pre-clinical studies, through clinical trials, and onto post-commercialization with translational continuity.  We aim to provide an industry-leading cadence of innovation and caliber of services – all fully customizable to meet your program’s needs.
* Visit the ClearPoint Neuro website for more information on the SmartFlow Cannula’s regulatory clearance.


LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be fully developed and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines.
Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and academic scientists. We are motivated by patient need and scientific opportunity.

Catalent Cell & Gene Therapy

Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. A full-service partner for plasmid DNA, viral vectors, vaccines and autologous and allogeneic cell therapies, Catalent has a global network of small- and large-scale clinical and commercial manufacturing facilities in the U.S. and Europe.

Parexel International

As a leading global CRO, Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, our therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in our DNA. What we do, we do With Heart.

Arranta Bio

Arranta Bio provides novel solutions to clients for advanced therapy process development and manufacturing. Our expertise and ability to provide end-to-end solutions for developing and manufacturing plasmid, mRNA, colloidal delivery systems including lipid nanoparticles (LNP) and the injectable sterile drug product, enabling our partners to gain speed-to-market advantage with next-generation mRNA products. We focus on partnership and tailor our solutions to each company’s unique needs.

Edinburgh Innovations

The unique skills, expertise and facilities at the University of Edinburgh offer a range of engineering biology tools and technologies to drive novel advanced therapeutics in Cell and Gene Therapy/Regenerative Medicine, Biomanufacturing and Drug discovery/development. We are actively pursuing a broad range of approaches from engineering novel AAV viral capsids, novel RNA polymerases for mRNA production, systems for controlling gene expression levels through to optimising existing Industrial CHO lines for increased yield and performance. Our Genome Foundry is the most advanced fully automated biofoundry worldwide which, coupled with our Beacon Optofluidic system, offers a rapid design-test-learn engineering biology cycle. This has been successfully utilised in several applications including therapeutic protein and biologics production from CHO, antibody discovery and we are looking for partners to use it for T Cell assays and selection.

IDT Biologika

IDT Biologika is a global contract development and manufacturing organization for vaccines, cell & gene therapeutics, oncolytic viruses, viral vectors and recombinant proteins for sterile liquid and lyophilized products. This includes end-to-end services from process development through drug substance manufacturing up to BSL-3, sterile liquid dosage filling & lyophilization, labeling & packaging to quality control & analytics.

We offer clients in B2B business a single source CDMO partner at our sites in Germany and the USA, with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialization. IDT Biologika handles every step in manufacturing and packaging of small clinical batches and large-scale commercial products.

Our fully integrated services at our sites in Germany and the USA are underscored by our commitment to quality and operational excellence that flows through our best-in-class process and cGMP (up to BSL3) manufacturing capabilities meeting FDA, EMA and ANVISA standards.

If you chose IDT Biologika, you receive reliable high quality services on products because we have the quality and supply mindset underlining the customer needs for speed to market.
We supply our client’s products in vials, pre-filled syringes, autoinjectors or as combination products.

IDT Biologika is unique in its ability to accommodate the development, testing and manufacture of products for the world’s leading biopharmaceutical companies. Many human vaccines developed by IDT Biologika, together with international partners, are already in use, fighting infectious diseases such as COVID-19, tuberculosis, AIDS, malaria, dengue, ebola and chikungunya.



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS.

To learn more about our commitments, please visit us at or follow us on Twitter (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).
PP-UNP-GBR-1982| September 2022


MaxCyte is a leading provider of cell-engineering platform technologies that are driving the next-generation of cell-based therapies and making a meaningful difference for patients. The Company's technology is employed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte has granted 13 strategic platform licenses to leading cell-based therapy developers. Through 2020, MaxCyte has granted licenses for more than 140 cell therapy programs, with over 100 licensed for clinical use. Our Flow Electroporation® technology and next-generation ExPERT® platform enable our partners to accelerate, streamline, and improve the drug development process from the early stages of research to commercialization. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, U.S.


Viralgen is a CDMO born as a joint venture between AskBio and Columbus Venture Partners, combining decades of technology and drug development experience in multiple platforms to support best-in-class service offerings to the gene therapy market.

Viralgen was created in 2017 in response to the unmet need for manufacturing of gene therapies. Our goal was to help broaden the access to these life-saving therapeutics and contribute to the advancement of health and human welfare around the world.

We specialize in the production of rAAV viral vectors. Our optimized facilities in San Sebastian, Spain, maximizes throughput and efficiency of our proprietary Pro10TM suspension manufacturing platform. This enables industry-leading scalability, reproducibility, and speed to market.

Through our superior technology platform, we deliver industry-leading titers and cGMP-certified quality for all AAV serotypes to our client partners, optimize the cost-of-goods and accelerate clinical development and commercialization of life-saving genetic medicines.


The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production. So more people will have access to better medicine.
Sartorius offers the Nutristem® and 4Cell® Nutri-T range of serum-free, xeno-free media for stem cells (MSCs, iPSCs, and ESCs) and T cells, which have become the gold standard in  research and clinical applications, helping to advance stem cell and lymphocyte based therapies.
Sartorius supplies additional related products for stem and T cell culture, including animal component-free freezing media, xeno-free attachment solutions and animal component-free cell dissociation solutions.

Thermo Fisher Scientific

As the world leader in serving science, Thermo Fisher Scientific is uniquely positioned to provide the quality materials, services and support need to accelerate the pace of advanced therapy development. We understand the complexity of this rapidly-evolving industry and have made significant investments in cGMP raw material manufacturing and drug product manufacturing capabilities to provide innovative end-to-end solutions- from the acquisition of Brammer Bio to investing to expand our critical raw material manufacturing facilities. Partner with us to access the high-quality materials, services, and support you need from discovery to clinical research and commercial cell and gene manufacturing. Through our Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab services, Patheon, and Gibco brands, we offer an unmatched combination of innovative technologies, manufacturing, and distribution capabilities.

PTC Therapeutics

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

Date of preparation: August 2022 | PTC/Corp/UK/22/0045



Genethon, is a pioneer and a leader in the field of gene therapy for rare genetic diseases. Genethon has multiple ongoing programs at clinical, preclinical and research stage for neuromuscular, blood, immune system, and liver diseases. Several of these programs are pursued by Genethon as sponsor, others have been licensed to leading biotech and pharma players in the gene therapy arena such as Avexis/Novartis (to which Genethon licensed the founding patents for Zolgensma), Audentes, Gensight Biologics, Orchard Therapeutics, Spark.
Genethon has around 200 scientists and experts in its R&D center in Evry (France), covering R&D, bioprocess development, clinical and regulatory.
Genethon is a non-profit organization created in 1990 by the AFM-Telethon (French Muscular Dystrophy Association) which is its main funding source.

Human Gene Therapy

Established in 1990, Human Gene Therapy is the leading peer-reviewed journal publishing exceptional, multidisciplinary research embracing all aspects of gene therapy — from basic research to new technologies to clinical development. The Journal publishes important advances in DNA, RNA, cell and immune therapies, and validates the latest advances in research and new technologies. Human Gene Therapy serves as the Official Journal of ESGCT.


MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology which allows tight, dose responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases.


The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.  


YPOSKESI, based in Corbeil-Essonnes, near Paris (France), is one of the largest European Contract Development and Manufacturing Organizations dedicated to the development and production of gene and cell therapy treatments. The broad expertise of YPOSKESI covers the production of Lentivirus & AAV viral vectors based on transfection processes, for pre-clinical development and clinical trials in compliance with the standards of Good Manufacturing Practice regulations. YPOSKESI benefits from the 30 years viral vector expertise of its long-standing partner, GENETHON, a major player in gene therapies for rare disease.
In addition, YPOSKESI has an experienced and efficient team of nearly 190 experts in Bioproduction, Quality Assurance, Quality Control, Project Management and Process Development, operating in a 5,000m2 (approx. 53,819 sq ft) modern GMP facility. YPOSKESI is also significantly investing in the development of innovative technologies for large-scale cost-effective manufacturing of these highly complex Advanced Therapeutics Medicinal Products. YPOSKESI plans to extend its production capacity by 2022, with an additional building including two suites dedicated to commercial manufacturing activities with a total of 10,000 m² (approx. 107639 sq ft) space.
By forging a solid industrial partnership with the South-Korean SK group, its majority equity shareholder, YPOSKESI reinforced its industrial strategy based on the technological expertise of SK pharmteco, the US SK’s affiliate, complementing that of YPOSKESI, and its solid experience in international manufacturing as a contract manufacturing organisation (CMO).


Synthego is a leading provider of genome engineering solutions. The company’s product portfolio includes software and synthetic RNA kits designed for CRISPR genome editing and research. With next-generation informatics and machine learning, Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.


CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics.

With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free inducible producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents nor cGMP plasmids. CEVEC’s CAP® Ad Technology is the ideal production platform for RCA-free Adenoviral vectors. Based on human suspension cells, it allows for a robust manufacturing process, easy scale-up from research grade to industrial volumes and thus opens the way for various applications, from gene therapy to vaccine production.

GenScript Biotech

GenScript is a world leader in biotechnology reagent services, providing life sciences services and products to over 200,000 scientists in over 100 countries worldwide. Established in 2002 in New Jersey, United States, the company was one of the first to commercialize gene synthesis as well as establish fully integrated capabilities for custom peptide synthesis, complex protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology, as well as a variety of other research-focused catalogue products.
After almost two decades of rapid growth, the company has expanded its business in recent years into the fields of immunotherapy, CDMO and microbiology to further its core mission of making people and nature healthier through biotechnological innovation.
With global support from its loyal customers and over 2600 employees located across the globe, GenScript continues to strive towards their vision of being the most reliable biotech company in the world, in service of a better and healthier future.


Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

TATAA Biocenter

TATAA Biocenter is a bioanalytical services company at the nexus of molecular biology, bioinformatics and high-throughput analysis, advancing research, clinical trials and diagnostic development. We lead the nucleic acid analysis market with proprietary techniques engineered to support your research needs more efficiently and precisely. We support academic and industry partners with assay design, workflow optimization and validation, quality control, multiomics analysis, data analysis, reporting, tech transfer, trainings, and sample management.


Founded in Indianapolis in 2014, Genezen is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide – making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers early-phase process development, GMP lentiviral vector production, retroviral vector production, and analytical testing services, building on the company's expansive knowledge and experience in the industry and working with the nation's leading institutions.


InnovaVector is a CDMO operator that specializes in the production of AAV vectors. We have ~20 years history of providing clients over 3000 R&D grade AAV vectors for research and preclinical studies for all major serotypes. We routinely solve our client’s vector or plasmid design requirements.

InnovaVector is expanding operations to provide material for phase I/II clinical trials, when our new state of the art GMP facility comes online in Q1 2023.

Our highly experienced scientific team with extensive cGMP background and broad AAV knowhow has helped us build an excellent reputation in AAV gene therapy world.

We bring Client’s innovative clinical idea to life – through AAV!

InnovaVector is a lively international working community with rapidly expanding career opportunities, that people aspire to work for. Located in subtropical Campania-region in Pozzuoli (Naples) on Mediterranean seashore and surrounded by ancient architectural recoveries, we provide modern healthcare solutions using AAV Gene therapy.

Center for Breakthrough Medicines

Center for Breakthrough Medicines (CBM) is an Advanced Therapy CDMO dedicated to addressing the challenges with bringing breakthrough therapies to patients. CBM offers pre-clinical through commercial manufacturing capabilities spanning process development; plasmid DNA, viral vector and cell therapy production; and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.


DiNAMIQS is a Contract Development and Manufacturing Organization (CDMO) revolutionizing gene therapy manufacturing and analytics. Based in Central Europe’s biotechnology hub Bio-Technopark Schlieren-Zürich, our state-of-the-art facility provides a comprehensive range of manufacturing services, process development, quality control and analytics solutions to support and optimize the most promising gene therapy projects. With our innovative customized business interaction solutions, DiNAMIQS accelerates time to the clinic for its partners while reducing cost and risk. Our facility offers potent genetic medicine delivery vectors including high quality recombinant adeno-associated viral (AAV) vector manufacturing suitable for both in vitro and in vivo R&D applications up to 50L scale. Our highly skilled team has demonstrated success in biomanufacturing processes with more than 20 years’ experience in the field. DiNAMIQS is currently building a GMP-compliant facility that can produce viral vectors at 500L scale.

Resolution Therapeutics

Resolution Therapeutics is a biotechnology company developing macrophage cell therapies for chronic liver disease. Founded in 2019 by Professor Stuart Forbes and Professor John Campbell from the University of Edinburgh in collaboration with Syncona, the company is pioneering the development of macrophages to treat inflammation and resolve fibrosis.
The company’s lead product is an autologous engineered macrophage therapy designed to treat liver cirrhosis. Chronic liver disease is the only chronic disease still on the rise in western countries, affecting millions of people worldwide. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors.

Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life-changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. With over 400 experts covering all aspects of advanced therapies, it applies its unique capabilities and assets, collaborates with academia, industry and healthcare providers to develop new technology and innovation. The Cell and Gene Therapy Catapult works with Innovate UK. For more information, please visit or visit



uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular technology platform to rapidly bring new disease-modifying therapies to patients treat patients with CNS, liver/metabolic and cardiovascular diseases.  We are advancing a focused pipeline of innovative gene therapies and have entered late-stage clinical development in our lead indication, hemophilia B, and have established preclinical proof-of-concept in Huntington’s disease.  

Oxford Biomedica

A leading, fully integrated, cell and gene therapy group focused on developing life-changing treatments for serious diseases, Oxford Biomedica is your partner of choice for viral vector development scale-up, analytics and GMP processing.
Leverage our expertise and state-of-the-art bioprocessing facilities and purpose built laboratories to help to achieve commercialisation of your viral vector-based products.

Using LentiVector®, our sector leading lentiviral vector platform, Oxford Biomedica develops in vivo and ex vivo products both in-house and with partners, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations.
Additionally, Oxford Biomedica has a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.
Discover how we drive credible science to help you realise incredible results - visit or email


REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the
curative potential of gene therapy. Our gene therapy product candidates are designed to deliver
functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or
antibodies that are intended to impact disease. Through a single administration, gene therapy could
potentially alter the course of disease significantly and deliver improved patient outcomes with long-
lasting effects.  We have developed a broad pipeline of gene therapy programs using our NAV ®
Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody
delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our
current programs and with our ongoing research and development, we expect to continue to expand
the platform.


OXGENE find solutions to seemingly impossible problems. We develop new technologies in mammalian cell engineering along the whole spectrum from discovery science to engineering at scale. Our unique combination of precision engineering and breakthrough science with advanced robotics and bioinformatics accelerates the rational design, manufacture and processing of complex biologics.
We work at the very edge of impossible to solve the problem of high titre virus manufacture for gene therapy treatments. We do this with high titre, high quality, suspension transient viral manufacturing systems, and with AAV and lentiviral packaging and producer cell lines. We address the challenge of speed and consistency in gene editing with our high throughput automated CRISPR platform, and we deliver the breakthrough needed to discover antibodies to membrane proteins through novel mammalian display techniques.

Orchard Therapeutics

At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment.

In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. 

Spark Therapeutics

At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We have successfully applied our technology in the first gene therapy approved in both the U.S. and EU for a genetic disease, and currently have five programs in clinical trials. At Spark, we see the path to a world where no life is limited by genetic disease. Spark is a member of the Roche group. For more information, visit, and follow us on Twitter and LinkedIn.


Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
For more information on Ultragenyx, please visit the Company's website at


AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit our website, and follow us on Twitter and LinkedIn.

Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company.  Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality.  Forge has a 175,000 ft2 facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters.  The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.  By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

WuXi Advanced Therapies

WuXi Advanced Therapies, a global Contract Testing Development and Manufacturing Organization (CTDMO), is the advanced therapies business unit of WuXi AppTec and offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies for customers worldwide. Our technologies, automation platforms and service solutions advance pre-clinical research and accelerate the timeline to GMP manufacture, while integrated GMP manufacturing and testing platforms reduce time to market, maintaining high titres, high levels of quality assurance and full regulatory compliance. Ultimately, our complete end-to-end solutions support pioneering companies to deliver breakthrough cell and gene therapies to the patients who need them.


Labcorp Drug Development, formerly Covance, is committed to helping you transform the future of healthcare by bringing promising cell and gene therapies to more patients. Our dedicated cell and gene therapy leaders—supported by a multi-disciplinary team of scientific, operational, medical and regulatory teams—can provide comprehensive and strategic insights for more efficient movement and reduction of risk across critical milestones of your entire therapeutic development journey. No matter where you are or where you intend to go, we’re here to provide the global infrastructure you need combined with the personalized experience you deserve. Labcorp Drug Development is part of Labcorp, a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Learn more about our comprehensive cell and gene therapy solutions at: 


We are SGS - the world’s leading inspection, verification, testing and certification company. SGS boasts a wealth of global health science expertise, supporting you every step of the way as you deliver first-class, fully compliant biopharmaceutical, pharmaceutical drugs and medical devices.
SGS Health Science has one core mission: improving patient health by safeguarding the quality and efficacy of medicines. Our first-class facilities and ongoing commitment to quality helps organizations build a healthier future. With over 35 years’ experience SGS offers an integrated CRO network of biopharmaceutical development and testing solutions to ensure compliance whilst accelerating drug development timelines.
SGS Glasgow is the global centre of excellence for Biosafety. We help clients satisfy regulatory requirements through a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and electron microscopy. The Biosafety services we provide demonstrate to health authorities that the biologics manufacturing is free of potential contaminants.


Perkin Elmer

With about 14,000 employees worldwide, we pioneer scientific technologies for better detection, imaging, and informatics to help our customers make a profound impact on the world. We provide support with advanced services to ensure optimal operations.


PlasmidFactory GmbH & Co. KG is a globally active biopharmaceutical company, founded in Bielefeld, Germany, in 2000. The leading contract manufacturing organization (CMO) for plasmid and minicircle DNA has a strong customer base in the fields of cancer research, gene and cell therapy, CAR-T cell development, and vaccination.

PlasmidFactory produces plasmids and minicircles according to client's requirements in modern laboratories with high quality standards.

The company's R&D activities are focused on its core competencies: Production, analysis and storage of plasmid and minicircle DNA. Furthermore, PlasmidFactory co-operates with national and international partners on individual projects, e.g. in the fields of CAR-T cell, AAV production and mRNA production.


We are Merck KGaA, Darmstadt, Germany the vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. Our products and services help you safely and efficiently develop and manufacture cell and gene therapies.
Our 30+ years of global expertise integrating leading manufacturing technologies with process development, scale-up, analytical development, and biosafety testing is here to help you accelerate your path to cures. Draw on our experience to bring your cell and gene therapies to life.

Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Since 1989, we have developed innovative and reliable technologies for scientists and clinicians around the world. Our integrated portfolio of tools covers techniques of sample preparation, cell separation, flow cytometry, cell culture, molecular analysis, and preclinical imaging. The MACS® brand has set standards worldwide and is trusted across basic, translational, and clinical research settings. Our expertise covers research areas like immunology, stem cell biology, neuroscience, and cancer, and clinical research areas that include hematology, graft engineering, as well as apheresis. We are committed to supporting scientists and the scientific community – from comprehensive technical support to training at our MACS Academy. Today, we are more than 3,800 employees in 28 countries – all dedicated to providing solutions that empower scientific discovery and advance cellular therapy.

Pall Corporation

Pall corporation offers fully integrated end-to-end bioprocessing solutions for gene therapy, from early process development projects to commercialization. Our dedicated teams of experts will work closely with you to overcome development and viral vector manufacturing obstacles to accelerate delivery of commercially viable gene therapies to patients.
Our extensive portfolio of upstream, downstream, and formulation and filling technologies is suitable for manufacturing different viral vector types in adherent or suspension-based processes.
Whether that means quickly developing a process, helping you ensure regulatory compliance, or making existing processes easier, faster and better, we are ready to work with you to address your process needs and accelerate your speed to market.
Please visit


GenoSafe provides analytical testing services for the evaluation of quality, safety and efficacy of Gene and Cell therapy candidates including:
· GLP biodistribution, shedding and immunogenicity studies;
· QC testing, such as viral titration, safety and potency/efficacy testing;
· GCP bioanalysis of patient samples, including immunogenicity, shedding and gene expression studies.
GenoSafe brings more than 15 years of experience in the development, qualification and validation of key analytical methods for product and sample testing.

Charles River Laboratories

The journey to market for a cellular or novel gene therapy is challenging given the unique and high specialized nature of each individual program, so it is crucial to choose a partner with proven experience developing these types of treatments and navigating the regulatory hurdles often associated with them. With over 70 years of experience, Charles River has a unique and comprehensive portfolio to support the development and execution of cellular and gene therapy programs from animal model selection to discovery and safety evaluations through to clinical and CMC testing support with expertise in a wide range of therapeutic areas. Our facilities in the United States, Canada, Britain, Finland, Netherlands, and Germany form a global scientific and regulatory network, allowing us to provide our clients with flexible, comprehensive solutions to optimize results and achieve milestones in order to make it to market on time. 


Founded in 1998, Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients worldwide rely on Aldevron-produced plasmid DNA, RNA, gene editing enzymes and more for biological research projects from discovery to clinical trials and commercial applications. These efforts help accelerate development of treatments for diseases such as cancer, infectious disease, pediatric disorders and rare diseases.  
Aldevron specializes in cGMP manufacturing and is known for inventing the GMP-Source® quality system. Our mission is to be a partner in the development of medicines that improve patients’ lives while serving clients, employees, and the community, while constantly looking for new and better ways to give researchers the products and services they need.  
Aldevron operates the largest cGMP plasmid DNA manufacturing facility in the world, located in Fargo, North Dakota, which serves as company headquarters, with additional production facilities in Madison, Wisconsin, and Lincoln, Nebraska.  


VIVEbiotech is a Contract Development and Manufacturing Organization -CDMO- developing and manufacturing lentiviral vectors under GMP standards with wide and robust experience in manufacturing vectors for rare/ultrarare diseases and for immune-cell therapy projects i.e. CAR-Ts, TCRs... 
VIVEbiotech is currently working on more than 35 projects according to both the FDA´s and the EMA´s regulations, and is manufacturing vectors for companies based in the US, Europe, Asia and Australia. 
VIVEbiotech has an R&D department as well as two process optimization departments for both upstream -USP- production and downstream -DSP- purification. The activities of these departments consist of improving the cost-effectiveness, scalability, regulatory or quality compliance of the production process, and the intrinsic biological characteristics of the vectors themselves.
VIVEbiotech very recently expanded facilities and has now seven cleanrooms fully and specifically set up for lentiviral-vector manufacturing. This has allowed significantly increasing our production capacity. 
In these facilities VIVEbiotech will be capable of manufacturing from early-stage to clinical- and commercial-scale batches.

STEMCELL Technologies

At STEMCELL, science is our foundation. Driven by our mission to advance research globally, we offer over 2,500 tools and services supporting discoveries in stem cell research, regenerative medicine, immunotherapy, and disease research. By providing access to innovative technologies such as organoids, gene editing, and specialized media, we’re helping scientists accelerate the pace of discovery.


The Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, is a world-renowned scientific institute devoted to improving public health by ensuring the safety and efficacy of vaccines and biomedicines both in Germany and throughout the world. PEI carries out its mission through scientific research and medicinal product regulation. Internationally competitive research is carried out in the fields of virology, microbiology, allergology, immunology, hematology and cell and gene therapy.

Sarepta Therapeutics

Sarepta Therapeutics is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.


Asphalion is an international Scientific and Regulatory Affairs consultancy, with offices in Barcelona, Madrid and Munich. We collaborate with Pharma and Biotech companies facilitating Drug Development and Regulatory Affairs projects for Drugs, Biologics, Biosimilars, ATMPs and Medical Devices. Our involvement ranges from early development, through to registration and post-commercialization phases. Since the company was founded in 2000, we have consistently grown and now have a team of over 80 employees with backgrounds in all areas of life sciences. Our consultants are experts in their fields and are in direct contact with European agencies for the implementation of new regulatory standards. We provide global services and work for hundreds of clients from around the world. Through collaborations with partners in all other continents, we can accelerate your worldwide scientific and regulatory activities by using local expertise.
• Regulatory and Scientific Strategy during Development
• Medical and Scientific Writing
• Global Submissions
• eSubmission and RIM
• Life-Cycle Outsourcing
• Pharmacovigilance
• Promoting the marketing registration of Medical Devices: Classification strategy, CE Marking and compilation of technical file. 

Clean Cells

A full range of regulatory tests in compliance with GLP and cGMP, with more than 200 qPCR tests available. Capability to develop and validate innovative, sensitive, specific and robust tests in accordance with ICH Q2 R1.
Production of Eucaryotic and Procaryotic cell banks, Viral banks and Storage in liquid nitrogen or -80°C.
Production of cell models which express molecules of interest.
Transfection, cloning, selection, amplification.
Analysis in vitro of the cell responses: measurement of viability, proliferation, phenotype, specific functions (ex. ADCC, apoptosis, CDC), interferon activity.
Development and validation of qPCR tests: detection quantification of pathogens or contaminants, residual DNA, determination of sites of insertion of a transgene, gene copy number.
Development and validation of virus titration method. 
Detection and validation of recombinant competent replication tests (rcAAV,RCL) for gene therapy.
GMP manufacturing platform for bacteriophages and cell therapy products for phase I / II clinical trials.


Biocair is a global specialist courier with over 30 years of dedicated experience in the pharmaceutical, biotechnology and life science sectors. Specifically, we provide dedicated, specialised logistics services – both the systems and the people – for the scientific sector and our services are the most comprehensive of its kind available on the market.

The company has built up a unique, client-centric approach by employing scientists in front- line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance amongst others. Biocair focuses on providing the most comprehensive time-sensitive and temperature-controlled logistics services available whilst delivering flexible, tailored, cost effective solutions to all clients.

The Biocair network spans more than 850 locations in over 160 countries across Europe, Africa, Asia and the Americas.

Univercells Technologies

Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand for viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.

Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 with the support of the Univercells group.


NHS Blood and Transplant is a national organisation within the NHS dedicated to saving and improving lives.

Our Cellular and Molecular Therapies function offers broad experience and expertise in the provision and manufacture of cell and gene therapies through our national network of GMP grade and MHRA licensed facilities.
NHSBT partner with academic, commercial and NHS organisations supporting novel cell and gene therapy programmes from concept through to clinical trial, operating a ‘not for profit’ model. 

We welcome expressions of interest for partnerships with organisations striving to develop the future of medicine in the advanced therapies space.


Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help customers (or the industry) optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.

GenIbet Biopharmaceuticals

GenIbet Biopharmaceuticals is a GMP biopharmaceutical CDMO offering highly specialized GMP manufacturing and development services. GenIbet core activity is the manufacture and supply of starting materials and Investigational Medicinal Products for use in early-stage drug development, pre-clinical studies and GMP manufacturing for clinical trials.

GenIbet expertise spans over a broad spectra of Biopharmaceuticals development, including recombinant proteins, Vaccines, RNA, Live Microbial Products and Cell and Gene Therapy products. GenIbet’s manufacturing portfolio includes a variety of mammalian, avian and insect cells, microorganisms and Viruses.

As of early 2022, GenIbet is part of Recipharm a leading CDMO, which is currently expanding its well-established capabilities on small molecules from preclinical-to-clinical and commercial approval to include new biological modalities such as viruses, viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Recipharm network on Biologics includes GenIbet, ArrantaBio and Vibalogics.

Takara Bio Europe

Takara Bio Europe is a leading manufacturer and supplier of molecular and cellular research reagents and services. With over 25 years of experience, our high-quality, innovative tools help to accelerate translational and clinical discoveries from the lab bench to the clinic.
We provide a reliable and consistent supply of reagents, from research to GMP grade. Our products include Cellartis® DEF-CS™ 500 Culture System and RetroNectin® GMP grade. With over 60 clinical trials using our products, they are recognized as worldwide standards for cell and gene therapy protocols.
Alongside our GMP production capabilities, we offer a wide range of genetic engineering and stem cell services. These services include sourcing, gene editing and cell banking. Our experts provide support and ongoing communication at every phase of your project giving you confidence in the success and timely completion of your project.

Batavia Biosciences

Batavia Biosciences is a biopharmaceutical CDMO with extensive experience in viral vector development and manufacturing projects. We offer our novel technologies and in-depth know-how in order to help our customers to complete preclinical phases at higher speed, reduced costs and increased success. The company focuses on the early stages of product development including cell line generation, upstream process development, purification development, product characterization and clinical manufacturing.

Stilla Technologies

Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including gene and cell therapies, cancer and liquid biopsy studies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA.


Many Tasks – One Name: Cellex Cell Professionals GmbH
Cellex is offering the complete spectrum of services in the field of cell and gene therapies for partners worldwide. Our scope is R&D, clinical as well as commercial manufacturing and testing.

Cellex started its operation in the very first field of cell therapy with the Cellex Collection Center in 2001 offering stem cell collections from unrelated donors for leukemia patients. Meanwhile Cellex runs the largest and with regard to allogeneic donations most experienced centers worldwide.

Today focused on CGT, Cellex manufactures as a CDMO in two state-of-the-art GMP facilities different cell products (intermediates, final products) using various techniques (separation, genetic modification using viral vectors, gene editing using CRISPR Cas, expansion and cryopreservation); all processes are adapted to customers` needs. Based on profound experience in EU and FDA regulations, Cellex stands for a successful tech transfer of processes from US to Europe and the other way around.

Cellex runs a registry with a highly diverse donor pool; together with the Cellex registry network we support R&D, clinical or commercial requests with customized cell products (leukopak, bone marrow, whole blood ….).

Centralized management using secure and efficient IT solutions and well established transport solutions round off the comprehensive Cellex portfolio.


The Bio-Manufacturing business unit is a cGMP accredited Contract Manufacturing Organization (CMO) that produces recombinant proteins and plasmids from microbial fermentation and IVT-RNA for clinical and commercial phases.
Eurogentec provides a wide range of services: process transfer and development, cGMP manufacturing, Quality Control, bulk release.

In 2020, Eurogentec launched a 1500L commercial line.
Plasmid: Cost-effective manufacturing of GMP starting material or injectable API pDNA.
rProtein: Significant experience in the protein production from Yeast (P.pastoris, S.cerevisiae, etc) and bacteria (E.coli).
IVT-RNA: Eurogentec is a pioneer in GMP in vitro transcript RNA. Our new facility can adapt to many different processes including availability of various modifications (co- or post-transcription).
With over 20 years of experience as CMO, you benefit from our broad manufacturing experience. Our philosophy is to establish a close partnership with our clients, adapt to their project needs and to provide them with cost and time efficient production processed.


Myriade develops the VIDEODROP, an innovative nanoscale imaging technology. 

Based on the principles of interferometry, the Videodrop makes it possible to measure the size and concentration of biological nanoparticles like lentivirus, adenovirus or retrovirus 

  • in real time (40s) 
  • in a single drop (5µL) 
  • between 80nm & 500 nm 
  • in a concentration range of 10E8 to 10E10 part/ml 
  • without labelling & no purification 
  • on viscous & complex samples 
Videodrop measures the physical titer of viral vector solutions, so it allows to: 
  • Continuously monitor bioproduction processes thanks to its rapidity of measurement (40s) 
  • Work on real samples at any stage of the bioproduction in a non-denaturant way 
  • Control the yield of vector production after harvesting, Purification, or Concentration steps 
  • Quickly identify lot-to-lot variations 

Providing linear results compared to p24 ELISA, VIDEODROP is suitable for "at-line" characterization of lentiviral vectors and in-process controls. 


ArcticZymes Technologies

ArcticZymes Technologies ASA is born from the unique conditions in the Arctic and our labs in Tromsø (Norway), we have been developing and producing cold-adapted enzymes for more than 30 years.
Our high-quality enzymes are an integral part of molecular research and diagnostics, either as stand-alone enzymes or as components of kits. In therapeutics such as gene therapy and vaccine production our enzymes aide the optimization of manufacturing processes.
All our products are manufactured to ISO 13485 standards and meet all REACH requirements. The unique features of our premium enzymes are accompanied by our dedication to quality, and a no-compromises approach to collaborate with our clients and partners.
ArcticZymes Technologies is trusted by leading molecular research kit manufacturers, diagnostic assay developers, contract manufacturers, and therapeutic companies around the world.


PROGEN - Making life science better. Together.

PROGEN was founded in 1983 by four scientists from Heidelberg, Germany, who joined forces to manufacture and supply high quality antibodies for biomedical research. We help scientists worldwide drive biopharmaceutical and diagnostic progress to provide high-quality and reliable treatments for patients. Our mission is to make new therapies safe and affordable and to improve existing research processes.
The PROGEN team consists of bioscientists and adeno-associated virus (AAV) experts who collaborate with specialists around the world. Our products are essentials for research in science and industry.
We are more than just a manufacturer of antibodies, AAV gene therapy tools, density gradient media, and phage display technologies: We strive to understand the needs of scientists to develop solutions to jointly address challenges in academic research, biotechnology and pharma.


VGXI, Inc. is a leading contract manufacturer of DNA-based pharmaceuticals with 20 years of experience providing high quality cGMP products to clinical trials worldwide. Uses include DNA vaccines, immunotherapies, and cell and gene therapy applications. The company's continuous, low-shear AIRMIX® lysis technology and optimized purification process provide highly supercoiled plasmid with exceptional purity across all manufacturing scales. Production services include high quality plasmid for preclinical research, Highly Documented (HD) plasmid as a critical raw material for GMP viral vector production or pharm/tox studies, and cGMP plasmid DNA for clinical through commercial supply. Pre-Clinical through GMP RNA manufacturing services are also available.

Beckman Coulter Life Sciences

Beckman Coulter Life Sciences is dedicated to developing and providing advanced technologies and equipment for research and discovery to explore new treatment methods. Our products include Liquid Handling and Genomic solutions, Particle Counting and Characterization, Centrifugation and Flow Cytometry, which are implemented in all major areas of Life Sciences such as biology, biochemistry, biophysics, nanotechnology and molecular biology to simplify and automate existing processes in the lab.

Our vision: Advancing science through discovery

Lonza AG

At Lonza, we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges.

Together, let’s bring your next medicine to life.


As a global pioneer in custom DNA vectors and recombinant viruses, VectorBuilder’s revolutionary online-to-offline (O2O) platform provides a powerful one-stop solution to all the vector and virus needs in the life sciences. VectorBuilder has a wide spectrum of offerings, including:

- Vector design
- Custom cloning
- Virus production (AAV, adenovirus, lentivirus, etc.)
- AAV capsid evolution and biodistribution services
- mRNA production
- Library construction
- Recombinant Protein Production
- Stable cell line generation
Additionally, our state-of-the-art GMP facilities provide GMP-grade plasmid and virus manufacturing for a wide range of clinical applications. 


PeproTech, part of Thermo Fisher Scientific, specialises in the development and manufacture of high-quality cytokine products for the life-science and cell therapy market. 

With more than 30 years’ manufacturing experience, PeproTech’s range of RUO, Animal-Free and GMP cytokines offers the performance and reliability that you need.

With over 2,000 products, PeproTech has developed and refined innovative protocols to ensure quality, reliability and consistency.

Our mission is to provide the highest quality products and premium support that address the needs and demands of today's scientists and researchers.

We pride ourselves on being a trusted partner within the scientific community.

Please contact PeproTech to request a quote or discuss your research requirements:

Tel: 020 7610 3062 or Email:

Aseptic Technologies

ASEPTIC TECHNOLOGIES manufactures innovative aseptic production equipment, designed to provide safer & easier aseptic filling operations.
The AT-Closed Vial® is provided ready to fill with its stopper secured in place, and sterilized by gamma irradiation.  The filling is performed by a special needle piercing the stopper, which is then immediately heat-resealed by laser and capped. The drug product is thus never in contact with the environment.

The AT-Closed Vial® ensures uncompromised Container Closure Integrity at -80°C and in vpLN2.

PackGene Biotech

PackGene is a leading CRO and CDMO company providing AAV-based gene therapy solutions to institutions and biotech companies. Ever since it was founded in Massachusetts in 2014, PackGene has been focused on providing expertise, reliability, scalability, and efficiency in AAV packaging services and AAV manufacturing.
PackGene has a 90,000+ ft 2  custom-designed cGMP facility, dedicated to plasmid DNA and AAV viral vector manufacturing, from GLP grade to GMP grade. We are experts in process development, scale-up as well as analytical testing. This is underpinned by a well-established safety framework, a track record of quality and compliance, a robust supply chain and access to skilled scientists.
Our goal is to collaborate with biotech companies and institutions to accelerate gene therapy programs from early discovery, preclinical stage through clinical, and on to commercial manufacturing.

Barkey GmbH & Co.

Barkey is a German family business for medical technology in the field of warming devices. Founded in 1980 by Volker Barkey, Thomas and Christian Barkey together with Armin Nowack and the entire staff have led the company to worldwide awareness in the hospital and blood bank sector as well as in cell & gene therapy research.

Barkey has two main goals: Preventing hypothermia and advancing Cell & Gene research to develop new cancer therapies. For this purpose, Barkey produces various solutions for warming or thawing blood, blood products and cellular materials, infusion solutions, etc. The safety of the samples, the user and, of course, the patient is of priority. Barkey relies exclusively on dry heating systems since the use of open water baths offers a high risk of contamination. This must be avoided both, during the preparation of patient treatment and during the research and production of new therapeutic procedures.

ChemoMetec A/S

ChemoMetec is a leading manufacturer of cell counting and analysis equipment. We specialize in developing and producing high-precision instrumentation that delivers consistent data for thousands of customers across segments including biotech, pharma, and academia.
Our NucleoCounter® instruments dominate the cell therapy space. They are the most robust and consistent cell counters on the market. What’s more, they are standardized for easy deployment across departments, and they are 21 CFR Part 11-ready, enabling you to fully integrate single or multiple instruments into your existing IT networks.
Designed, manufactured, and tested in Denmark, we build our instruments and consumables with quality materials and dedicated expert workmanship.


Standard BioTools

Standard BioTools manufactures, and markets technologies and life science tools focused on the production and manufacturing of gene and cell therapy products. From sensitive and in-depth single-cell characterization of cell therapy products with single-cell genomics with the C1™ system, to the possibility of monitoring the in-depth phenotype and function of these products with ready-to-use high-dimensional cytometry assays, Standard BioTools accelerates all aspects of the research field within the cell and gene therapy space.


Mission Bio

Mission Bio is a life sciences company that enables comprehensive characterization of your cell and gene therapy candidates for safer and more effective therapeutics. The company’s Tapestri Platform empowers developers to accurately assess multiple genotypic attributes in a single assay, including on- and off-target gene editing, zygosity, chromosomal aberrations, transduction efficiency, and vector copy number— in 1000s of individual cells. The platform’s robust multi-omics capability enables DNA and cell-surface proteins to be co-measured in the same cells, providing information on genotype and cell type/ state. Mission Bio partners with biopharma to provide full-service Pharma Assay Development — including experimental design, lab work, and bioinformatic analysis — so you can leverage single-cell analysis in your preclinical, clinical, and commercial efforts.

Unchained Labs

Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.

Proteintech Europe

Proteintech manufactures antibodies, immunoassays, HumanKine recombinant proteins and ChromoTek Nanobody-based reagents.
Proteintech’s comprehensive library of original validation data, product-specific protocols, and over 130,000 product citations enables you to publish faster with reproducible results.   

  • Antibodies against over 13,000 human targets
  • Immunoassay kits
  • RUO and GMP HumanKine cytokines and growth factors
  • ChromoTek Nanobody-based reagents
  • Supporting tools and reagents

 Browse the full product range at or contact to learn more about our products and promotional offers.


Samplix supports the life sciences and medical research communities with proprietary microfluidics-based solutions designed to deliver the highest-resolution insights into cells and genomes. Our technology encapsulates single mammalian, bacterial or yeast cells, DNA, and other biological material together with assay chemistry. This supports a range of downstream analyses: functional analyses of single mammalian cells, assessments of single-cell enzyme activity, characterization of edits in engineered genes, and even cell incubation. As a leading developer of microfluidics solutions, Samplix stands ready to help researchers reach their goals in areas as diverse as gene and cell therapy, synthetic biology, and molecular engineering.

SIRION Biotech

SIRION Biotech GmbH is a leading commercial supplier of viral vector technologies (AAV, LV, AV). Our viral vector know-how enables engineering for a new generation of optimized vectors.
We guide our customer through the entire Cell & Gene Therapy value chain – from capsid evolution and clinical vector design to reduce vector dose and improve therapeutic success, to supporting them with our process and development experience and manufacture of high-quality clinically compliant viral vectors for late preclinical applications.
We also offer LentiBOOST®, a highly effective lentiviral transduction enhancer for therapeutic cell types like CAR-T cells and CD34+ hematopoietic stem cells. LentiBOOST is currently included in more than 20 Phase III and I/II clinical trials and is available in research and GMP grades.
The company is located near Munich with offices in Paris and Boston. Commercial arrangements range from fee-for-service and IP-generating collaborations to milestone & licensing arrangements.

Grifols Bio Supplies

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.

The Bio Supplies Division supplies high-quality biological materials for biotechnology research, clinical trials, and for manufacturing pharmaceutical and diagnostic products.

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.

Andelyn Biosciences

Andelyn Biosciences is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, full quality system/regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 16+ production suites for customization of new programs and tech transferred programs as of 2H 2022, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients.

JPT Peptide Technologies

JPT provides products and services for all the development phases of next generation immunotherapeutics. With sound knowledge in immunology and peptide chemistry, we offer peptides and peptide pools (PepMix™) for antigen-specific stimulation of cells, humoral and cellular epitope mapping, viral transduction, and development of immunotherapies. 

Thanks to an enhanced production protocol, our peptides are the product of choice for the development of cell therapies such as adoptive cell transfer or dendritic cell pulsing independent if you are aiming for an individualized neo-epitope approach or working with shared and common antigens. 

With our novel transduction enhancer Protransduzin™ the generation of CAR-Ts or TCR-Ts can be streamlined by enhancement of viral transduction in a simple one-step protocol.  Humoral immune response is addressed with our PepStar™, high-content microarrays for seromarker discovery and multiwell microarrays for profiling up to 20 samples.


Symbiosis Pharmaceutical Services is a contract development and manufacturing organisation (CDMO) specialising in the GMP manufacture and sterile fill/finish of vials for clinical trials and commercial supply. Regulatory compliance, technical capability and operational flexibility are at its core.
Manufacturing from a purpose-built FDA inspected and MHRA-licensed facility, the CDMO can handle products that require aseptic liquid filling and lyophilisation for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs.
Offering fast access to manufacturing slots and accelerated release of drug product, Symbiosis is primed to meet demand for small-scale, fast-turnaround drug product sterile manufacturing.


Kriya is a fully integrated gene therapy company on a mission to revolutionize how gene therapies are designed, developed, and manufactured – with a goal of improving speed to market and reducing cost. The company leverages its proprietary computational engine, in-house manufacturing infrastructure, and integrated design platform to engineer products with the potential to transform the treatment of a broad range of diseases. Kriya’s team includes scientific pioneers with decades of experience in product development, complex manufacturing, and computational engineering.

The company has established an ecosystem for delivering best-in-class technologies and medicines, with core business units in technology, manufacturing, R&D, and therapeutics. Kriya’s product pipeline addresses diseases of high unmet need with therapeutic area divisions in ophthalmology, oncology, rare disease, and chronic disease, each led by industry veterans with a track record of advancing products from concept through commercialization. Built upon this foundation, Kriya achieves the scale needed to drive transformational improvements in the engineering, production, and translation of gene therapies. 

FUJIFILM Irvine Scientific

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. We provide unrivaled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and bioproduction for commercial manufacturing of biotherapeutics and vaccines.

Our commitment to supporting the biopharmaceutical industry in the successful development and commercialization of human therapeutics and vaccines is evident in the alignment of our technology, support, and supply capabilities to meet and exceed the distinctive requirements of the market. While remaining a uniquely flexible and focused media company for over 50 years, FUJIFILM Irvine Scientific has steadily advanced as a strategic global supplier in support of our customers from early development to commercialization.


Evotec is a life science company with a unique business model focused on providing access to highly effective new therapeutics. The Company leverages its multimodality platform with a unique set of innovative technologies for both proprietary and partnered projects.

Halo Labs

Halo Labs knows aggregates and particles. The Aura can count and characterize subvisible particles and tell you if they are aggregated drug product, excipients, or external contaminants. A simple, plate-based approach enables low-volume, high-throughput, fully automated particle imaging and analysis at any stage from developability assessment through quality control.


For 40+ years, QuickSTAT has been providing the leading pharma and biotech companies 24/7/365 global life science logistics solutions, from R&D, clinical trials through to commercialization.

Our team of logistics experts provide time- and temperature-sensitive shipping of clinical research samples, cell and gene therapies, investigational drugs, clinical trial supplies and vaccines, helping bring new drugs to market.  Strict chain of custody, chain of identity and GDP protocols ensure product integrity and patient safety. QuickSTAT provides customized temperature control solutions and consultation/ procurement of proper packaging—from refrigerated to cryofrozen. Advanced logistics tools provided for managing your supply chain.


ReiThera is a biotech company with a long-standing expertise in the development of scalable processes for viral vector manufacturing and has a consolidated experience in the GMP production of Adeno Viral vector (AdV), Adeno Associated Vector (AAVx), Lentivirus (LV), MVA, HSV and other.
ReiThera bases its core manufacturing capacity in a state-of-the-art facility including stirred-tank bioreactors at the scale of 50L, 200L, 1000L and 2000L and fixed bed bioreactors for cell growth in adherence. The GMP facility is inclusive of filling suite and quality control laboratories.
In addition, ReiThera has a consolidated experience in immunology and in the set-up of immuno-profiling studies focused in the monitoring of the immune responses to pathogens, vaccines, gene-therapy and immunotherapeutics during preclinical and clinical trials.


Refeyn, the mass photometry pioneer, offers new capabilities to characterise the function, structural composition and dynamics of biomolecules. Refeyn instruments measure the mass of individual molecules directly in solution, quickly and simply revealing the true behaviour of molecules in near-native environments.  The diverse applications of mass photometry include quantitative analysis of sample purity and homogeneity, biomolecular complex assembly and disassembly, the strength and kinetics of molecular interactions, and more. Refeyn was spun out of Oxford University in 2018 to make mass photometry available globally. Its technology has now been rapidly adopted across academia and industry, where it is transforming biomolecular characterisation.  The TwoMP, Refeyn’s mass photometer, brings the technology into everyday laboratory life, enabling molecular measurements with unprecedented speed and simplicity. It uses proprietary technology to detect the light scattered by single molecules in solution, delivering label-free mass measurements over a broad mass range with high precision and exquisite sensitivity.

Alfa Wassermann

Zonal Ultracentrifugation Solutions
AWST provides zonal ultracentrifugation solutions that efficiently and reliably separate viruses, virus like particles and viral vectors for the development and manufacture of vaccines, gene therapies, and other bio-products.  From research scale to full production, our patented core technology makes linear scalability possible with no revalidation or compromise of yield and purity.  AWST ultracentrifugation systems reliably remove empty capsids to undetectable levels.  With the addition of the AWST Automated Fluid Handling (AFH), customers now have a system that fully automates and standardizes the critical process of fluid filling and fractionation in a self-contained mobile work station. 


RoslinCT is a leading Cell & Gene Therapy CDMO enabling you to bring your autologous or allogeneic therapy safely to the patient. Based at the Edinburgh BioQuarter, we operate a fully licensed GMP manufacturing facility and have a proven track record in the delivery of cell-based products.

We offer a range of integrated services from technology transfer, process and assay development through to GMP manufacturing, storage, QP certification and batch release of cell-based therapies for clinical trials.

At the heart of RoslinCT is a dynamic, highly experienced team that will understand your goals and will partner with you to get your therapy to market efficiently and effectively.


ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies. 


SynGenSys (Synthetic Genetic Systems) creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes. Our philosophy is simple: all products and production processes are unique. Therefore, core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for specific purpose. Our platform technology harnesses years of research and development with bioindustrial partners. We engineer novel synthetic genetic parts from the ground-up, based on bioinformatic analysis of streams of genome-scale information pertinent to the biological system and user-defined design criteria.

Gene and Cell Therapy: DNA Engineering for Cell Type Specificity and Control. Transfer of therapeutic DNA or mRNA into human cells underpins many new strategies to treat disease. However, precise targeting and control of gene expression remains a fundamental challenge. Our design systems create novel libraries of cell-type specific promoters with a minimised DNA footprint that provide user-defined control of therapeutic transgene expression.


Exothera is a viral vector CDMO (contract manufacturing and development organization) using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing and provides QC services and analytical development.


c-LEcta – for tomorrow’s industry
c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the pharma and food industries. c-LEcta’s proprietary GMP endonuclease DENARASE® and the associated ELISA kit are widely applied in the manufacturing of viral vectors for gene/cell therapies and vaccines, both on clinical and commercial scale. DENARASE® is manufactured under EU GMP conditions in Germany and comes with extensive regulatory documentation (including US FDA Drug Master File and compliance with EXCiPACT/ANSI NSF 363). c-LEcta is based in Leipzig and currently
employs more than 100 people.


CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

Founded in 2009 in Tübingen, Germany, the company combines state-of-the-art sequencing technology with medical expertise – with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumour analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights.

The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality. CeGaT's laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO/IEC 17025 and thus meets the highest international standards. To obtain first-class results, all processes are carried out in-house under scientific supervision.


BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across a number of industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies.

VDO Biotech

VDO Biotech Co., Ltd. is a high-tech enterprise dedicated to innovative microsphere technologies and the production of a variety of high-quality microsphere products for global customers. The headquarters of VDO is located in the BioBAY of Suzhou Industrial Park in, China, with ISO9001:2015 certified manufacturing facilities and a total area of facilitates of more than 10,000 square meters. Our dedicated staff is your reliable partner for the solution of any microsphere-related applications.
VDO Biotech is deeply engaged in the large-scale microsphere production and application for in vitro diagnostic. We not only provide microspheres of uniform and controllable particle size, nano-sized & micro-sized microspheres with high quality and a variety of surface functional groups, but also provide customized services of various types of microspheres, large-scale microsphere conjugation services with antibodies or nucleic acid probes, OEM services for microspheres and intermediates, and complete solutions for microsphere applications.

Powered Research

Powered Research is a preclinical CRO specializing in non-GLP ophthalmic models for life science R&D companies. We offer services that range from supporting clients' early research to creating custom ophthalmic models to fit their unique needs. Our offerings include tolerability, efficacy, and pharmacokinetics with fully customizable models for all stages of pre-clinical development.


TAAV Biomanufacturing Solutions is advancing gene therapy by offering its synthetic, linear, double stranded DNA, dbDNA, as the new industry standard for transfection-based AAV production. We believe it is a safer, more effective, more scalable and a faster way to manufacture AAV.


BPES connect knowledgeable consumers with market-leading innovators of specialist scientific instruments and industrial equipment used in biotech, biopharma and cell and gene therapy.  BPES work with largely UK based clients sourcing their equipment from suppliers across Europe.  . BPES are proud to showcase SYNENTEC and CARR Biosystems at ESGCT 2022
SYNENTEC are specialists in high-throughput imaging and automation in CLD and science. SYNTENTEC have developed automated, high throughput cell culture microscopes and fast, easy to use image analysis software.  The instruments are used throughout the industry for applications varying from rapid and precise single cell cloning through to high content imaging studies using fast fluorescent multiplexing and bespoke image processing features.
CARR Biosystems wide range of separation equipment accelerates the production of high-quality biological products and medicines, allowing for seamless scaling up, down, or out.  The UniFuge® family provides low-shear separation, high-recovery performance and fast processing time. With three sizes, the UniFuge enables linear scaling, providing seamless transition from benchtop process development to commercial manufacturing.
Come and visit us on stand 78


ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies. ABL's mission is to provide GMP viral vectors from early-stage to market, contributing to the success of their clients' immunotherapy innovations. ABL's CDMO services include bulk drug substance, fill/finish of drug products, process and assay development, and bioanalytical testing. ABL is a subsidiary of the Institut Mérieux. They operate from various locations in Europe and the US.


ProtaGene is a world leading CRO partner for the gene and cell therapy industries.
From discovery to product commercialization, ProtaGene provides the most advanced, integrated, and complete protein and gene analytic capabilities and packages for cell & gene therapy platforms.
A unique combination of gene- and protein based analytical platforms provides our clients unique expertise for cell & gene therapy and biologics development for MLA and BLA submission. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.

Fios Genomics

Fios Genomics provide a wide range of bioinformatics analysis services to pharmaceutical and biotechnological companies, CROs and academia, supporting drug discovery and development and applied research across all species. We focus on quality, excellent customer service and a commitment to jargon-free bioinformatics service provision across all data platforms for all aspects of life sciences.
Using the best-in-class tools and methods, Fios provide a functional and interactive reporting architecture, allowing scientists to fully explore their data. We can analyse ‘omics data in combination with other outputs from experiments or trials such as imaging data and clinical information. This helps to build up the data picture while ensuring that a robust analysis is delivered.
Our team is a combined resource of in-house bioinformaticians, statisticians and biologists working together to analyse and interpret high-volume, high-dimension data including those generated with:

  • next generation sequencing,
  • microarrays,
  • proteomic, metabolomic & lipidomic platforms


Spun out of Newcastle University (UK) in 2017 by the three co-founders, Professor Che Connon, Dr Steve Swioklo and Dr Mick Mclean, Atelerix have designed an innovative approach to the storage and transportation across the world of fresh cells, tissues, and viruses.

Our approach treats cells as the fragile, sensitive, living entities that they are. Our aim is to protect biological products from biochemical and physical damage, retaining viability and function without the need for cryopreservation.

Our plant-based hydrogels are pharmaceutical grade high purity alginates. Cells, tissues, or viruses are encapsulated by the gel which stabilises lipid membrane integrity during hypothermic storage. Cells live and in a state of "hibernation" allowing them to be safely stored and/or shipped for extended periods of time. When required they are quickly "awoken" upon return to physiological temperatures in the same state they entered.

Our products extend the time that biological samples can be stored at hypothermic temperatures resulting in a consistently high yield, viability, and function for longer.


iotaSciences offers services and instrumentation to support cell line engineering for the cell and gene therapy market. Our flagship product, the cloning platform delivers powerful automation, high cloning efficiency and documented proof of monoclonality to accelerate the development of stable cells lines for genome-edited iPSC and viral vector manufacture. In addition, the platform uniquely automates all the fluid-handling and image-capturing steps of the single-cell cloning workflow making it easier than ever to obtain document monoclonality, clone tracking and data management on a single platform.

Rentschler ATMP

Rentschler ATMP was launched by Rentschler Biopharma in 2021 to provide high-quality viral vectors for advanced therapy medicinal products (ATMP).

Rentschler Biopharma is a leading global CDMO, focused exclusively on client projects. Thanks to our 50 years of proven scientific expertise in biotechnology, we count ourselves among the leaders in the industry. From our headquarters in Laupheim, Germany, and our site in Milford, USA, we offer end-to-end solutions including biopharmaceutical process development and cGMP manufacturing.

Our Center of Excellence for cell and gene therapy is located in the UK largest cell and gene therapy cluster Stevenage. At Rentschler ATMP, we are dedicated to advancing cell and gene therapy products from development to cGMP manufacturing for our clients and their patients.

Eppendorf SE

Stimulating Growth. Cultivating Solutions. – Expert Partner in Stem Cell Bioprocessing

Large cell numbers are needed for the development of cell therapies, stem cell-based drug research and future applications such as lab grown meat. By utilizing its strong synergies in cell culture expertise, bioreactor technology, and polymer manufacturing, Eppendorf has emerged as an expert partner for the cultivation of stem cells at large scale.

With our equipment, training programs, and application services, we support scientists in resolving cultivation bottlenecks during the development of advanced stem cell-based applications. The need for advanced solutions is constantly increasing. With our expertise, we help to stimulate the growth of your cultures and cultivate solutions tailored to your challenges.

Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid handling, cell handling and sample handling. Today, Eppendorf and its more than 4,000 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world.